AR121183A1 - Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17) - Google Patents

Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)

Info

Publication number
AR121183A1
AR121183A1 ARP200103171A ARP200103171A AR121183A1 AR 121183 A1 AR121183 A1 AR 121183A1 AR P200103171 A ARP200103171 A AR P200103171A AR P200103171 A ARP200103171 A AR P200103171A AR 121183 A1 AR121183 A1 AR 121183A1
Authority
AR
Argentina
Prior art keywords
antagonists
lupus nephritis
interleukin
treatment methods
treatment
Prior art date
Application number
ARP200103171A
Other languages
English (en)
Inventor
Luminita Pricop
Wolfgang Hueber
Shephard Mpofu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR121183A1 publication Critical patent/AR121183A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a métodos para el tratamiento de la Nefritis Lúpica (NL) usando antagonistas de IL-17, por ejemplo, secukinumab. Además se divulgan antagonistas de IL-17, por ejemplo, anticuerpos IL-17, como secukinumab, para el tratamiento de pacientes con NL, así como medicamentos, regímenes de dosificación, formulaciones farmacéuticas, formas de dosificación y kits para su uso en los usos y métodos divulgados.
ARP200103171A 2019-11-19 2020-11-17 Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17) AR121183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962937482P 2019-11-19 2019-11-19

Publications (1)

Publication Number Publication Date
AR121183A1 true AR121183A1 (es) 2022-04-27

Family

ID=73598917

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103171A AR121183A1 (es) 2019-11-19 2020-11-17 Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)

Country Status (11)

Country Link
US (1) US20230009657A1 (es)
EP (1) EP4061418A1 (es)
JP (1) JP2023502103A (es)
KR (1) KR20220103141A (es)
CN (1) CN114728060A (es)
AR (1) AR121183A1 (es)
AU (1) AU2020386669A1 (es)
CA (1) CA3161801A1 (es)
IL (1) IL292926A (es)
TW (1) TW202120546A (es)
WO (1) WO2021099924A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240041870A1 (en) * 2022-07-28 2024-02-08 Abbvie Inc. Methods of treating systemic lupus erythematosus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
SI2481753T1 (en) 2005-12-13 2018-06-29 Eli Lilly And Company Anti-IL-17 antibodies
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
CN102617735B (zh) 2008-09-29 2015-09-09 罗氏格黎卡特股份公司 针对人il17的抗体及其应用
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
LT3111954T (lt) 2010-11-05 2019-07-10 Novartis Ag Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
HUE047119T2 (hu) 2013-02-08 2020-04-28 Novartis Ag Anti-IL-17A antitestek és alkalmazásaik autoimmun és gyulladásos betegségek kezelésében
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17

Also Published As

Publication number Publication date
WO2021099924A1 (en) 2021-05-27
TW202120546A (zh) 2021-06-01
CA3161801A1 (en) 2021-05-27
US20230009657A1 (en) 2023-01-12
JP2023502103A (ja) 2023-01-20
IL292926A (en) 2022-07-01
CN114728060A (zh) 2022-07-08
AU2020386669A1 (en) 2022-06-02
EP4061418A1 (en) 2022-09-28
KR20220103141A (ko) 2022-07-21

Similar Documents

Publication Publication Date Title
NI202000078A (es) Compuestos heteroaril tetracíclicos
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
MX2020003661A (es) Formas de dosificacion de liquidos, metodos de fabricacion y uso.
CL2018003438A1 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos.
UY37142A (es) Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CO2019012473A2 (es) Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
UY35293A (es) Isotiazoles sustituidos con amino
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
UY37456A (es) Inmunoglobulinas y sus usos
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
DOP2021000104A (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
CO2018012506A2 (es) Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
AR121183A1 (es) Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)
BR112022004941A2 (pt) Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)